MedTrace Logo

DISCOVERing Treatment Reality of Type 2 Diabetes in Real World Setting in Japan

NCT02226822 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1869

Last updated 2020-02-07

No results posted yet for this study

Summary

This study is intended to prospectively research the treatment reality and long-term disease control of Type 2 Diabetes Mellitus (T2DM) patients who are initiating 2nd line anti-diabetes treatment in sites across Japan.

Conditions

Sponsors & Collaborators

  • Ono Pharmaceutical Co. Ltd

    collaborator INDUSTRY

  • AstraZeneca

    lead INDUSTRY

Principal Investigators

  • Kiyoshi Hashigami, M.D. · AstraZeneca

  • Iichiro Shimomura, M.D., Ph.D. · Department of Metabolic Medicine (Internal Medicine), Graduate School of Medicine, Osaka University

  • Hirotaka Watada, M.D., Ph.D. · Department of Metabolism & Endocrinology, Graduate School of Medicine, Juntendo University

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-20
Primary Completion
2019-02-12
Completion
2019-02-12

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02226822 on ClinicalTrials.gov